Friends of Cancer Research’s Post

Lung-MAP is a first-of-its-kind clinical trial model that uses a multi-drug, targeted screening approach to match patients with sub-studies testing investigational new treatments based on their unique tumor profiles. #LungMap https://lnkd.in/e-ARUbx6

𝐂𝐚𝐥𝐥𝐢𝐝𝐢𝐭𝐚𝐬 𝐀𝐧𝐧𝐨𝐮𝐧𝐜𝐞𝐬 𝐏𝐨𝐬𝐢𝐭𝐢𝐯𝐞 𝐃𝐚𝐭𝐚 𝐟𝐨𝐫 𝐒𝐞𝐭𝐚𝐧𝐚𝐱𝐢𝐛 𝐢𝐧 𝐒𝐂𝐂𝐇𝐍 𝐓𝐫𝐢𝐚𝐥 Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) Calliditas Therapeutics announced positive data from the Phase 2 trial of setanaxib in combination with pembrolizumab for squamous cell carcinoma of the head and neck (SCCHN). The trial showed significant improvements in progression-free survival (PFS) and overall survival (OS), along with changes in tumor biology consistent with setanaxib's mechanism of action. The trial involved 55 patients with recurrent or metastatic SCCHN. Patients receiving pembrolizumab and setanaxib demonstrated significant improvements in key secondary endpoints compared to those receiving pembrolizumab and placebo. Transcriptomic analysis showed an increase in CD8+ T-cells in setanaxib-treated patients. "The results provide a strong basis for advancing setanaxib," said Professor Kevin Harrington. CEO Renée Aguiar-Lucander Renee Aguiar-Lucander expressed excitement about the positive clinical evidence supporting their NOX platform. CMO Richard Philipson Richard Philipson thanked the trial participants and investigators for their contributions. Calliditas is conducting additional trials with setanaxib, with readouts expected in Q3 and Q4 of 2024 and 1H 2025. An R&D day in Stockholm will provide further details. #CalliditasTherapeutics #Setanaxib #SCCHN #CancerResearch #Immunotherapy #ClinicalTrials #Biopharma #MedicalInnovation #NOXInhibitor #SurvivalImprovement

This is the first time EVER that an #IHC test has received tumor – agnostic #FDA approval. Huge congratulations to #AstraZeneca and #DaichiSankyo on yet another historic milestone. 👏👏 Hopefully, this is a harbinger of approvals to come as the pipeline for #ADC therapies is robust. With this unprecedented approval, we are likely to see an acceleration in the use of #PrecisionDiagnostics. The implications for patient care are enormous. Every patient with an advanced solid tumor malignancy will have the opportunity to be tested and potentially benefit from this highly innovative and efficacious therapy. Laboratories will need to come together to make testing readily available and democratize eqiutable patient access to #PrecisionOncology. Testing is available at #PathGroup. We have been working diligently to optimize testing here. #HER2 #cancerdiagnostics #precisionmedicine #Enhertu #GenomicEducation #GE

Proud to have been able to contribute to this research. Another great article, assessing ADC and recombinant photo-activated therapeutic efficacy for light-accessible and light-inaccessible tumors. https://lnkd.in/dFwTibUM

Curadev is thrilled to introduce CRD3874, a first-in-class allosteric #smallmolecule #STINGagonist, with distinct pharmacological properties that distinguish it from agents that bind to STING's cGAMP site. "CRD3874 is clearly unlike CDN-competitive STING agonists, since its distinct pharmacology and tolerability appear to be related to its allosteric binding mode. We are hopeful that the promising preclinical studies presented here will speak to the therapeutic potential of immune activation by CRD3874-SI in the context of advanced cancer in humans," said Monali Banerjee, VP R&D at #Curadev, who leads the STING programs. ➡️ Read the full announcement from Yahoo Finance:

BioProcess International has published an insightful article featuring our CEO, Dr. Ofer Sharon, on the challenges of estimating #ICI suitability in #cancertreatment. 🧬 Ofer highlights the urgent need for a paradigm shift in how researchers and IVD developers approach #biomarkers for treatment suitability, especially in light of the limitations surrounding PD-1/PD-L1 as predictors of ICI success. 🧠 OncoHost is pioneering a new way to address this complexity by leveraging AI/ML to analyze #proteomic data from patient blood plasma. Our platform provides oncologists with accurate, actionable insights into tumor resistance, helping them make informed decisions about ICI-based therapies. Read the full article to learn more about our innovative approach and how it’s shaping the future of precision oncology! 🔗https://lnkd.in/dP6wq3Rm #PrecisionOncology #AI #CancerResearch #Proteomics #ICITherapy #Biotech

This recent review of the latest clinical developments in GBM (immunotherapy and targeted approaches) offers interesting perspectives for early drug discovery and development: 🎯 Improve drug delivery system 🤝 consider combos, including immune combination therapies and better explore interaction between SoC and your lead before clinical trials. 💻 huge need for big data technologies and intelligent experimental platforms to overcome tumor heterogeneity (inter patient, intra-tumor and over recurrence) as well as the complex role of tumor micro-environment https://lnkd.in/e2XpTHW6

The widely-used drug sensitivity score (DSS) developed at FIMM by Tero Aittokallio's team has been extensively upgraded for more robust quantification of selective drug responses in patient-derived cells. The novel features in the open-source software, together with new reference response profiles from healthy individuals, support systematic identification of candidate compounds for effective and safe personalised therapies. The team has demonstrated the applicability of the software in various precision medicine study settings in collaboration with other Nordic cancer centers. The results of this joint work have just been published in Nature Protocols. #cancer #cancerresearch #precisionmedicine #drugresponse #bioinformatics #software #opensourcesoftware

KCR in The News 📰 KCR Chief Medical Officer, Dr. Anna Baran and KCR Principal Consultant, Dr. Dave Li's article, "Elements in Precision Oncology" has been published in pharmaphorum. The authors highlight critical issues in the clinical development of predictive #biomarkers for precision #oncology and offer insights on key elements of study designs for #data collection and analysis. Check it out! https://lnkd.in/e2fgDsxX #KCRCRO #Consulting #KCRSolutions #KCRBiosimilars #safety #stability #research #clinicaltrials #clinicalresearch

🔬 #AACR24 𝐂𝐥𝐢𝐧𝐢𝐜𝐚𝐥 𝐃𝐚𝐭𝐚 & 𝐒𝐭𝐨𝐜𝐤 𝐌𝐨𝐯𝐞𝐬 📈 At this year's #cancer conference we saw not just pre-clinical, but also new clinical data… Here's a glimpse at some clinical readouts and how stocks reacted 👇  Get updates like this each week → https://lnkd.in/gGSgpiJM Kazia Therapeutics Limited (NASDAQ: KZIA) Readout details: Ph1 initial data of EVT801 Indication: Advanced Solid Tumors Results details: Safety data on first enrolled patients showed no safety alert which allows further dose escalation Elicio Therapeutics (NASDAQ: ELTX) Readout details: Updated Ph1 data from AMPLIFY-201 Indication: Pancreatic & Colorectal cancer Results details: The majority of ELI-002-treated patients tested had antigen spreading where induced T cells targeted additional patient-specific tumor mutations beyond mKRAS & observed to have durable mKRAS-specific T cell response with increased memory T cell phenotype. RAPT Therapeutics (NASDAQ: RAPT) Readout details: Ph2 data of tivumecirnon in combo w/ pembrolizumab Indication: Solid Tumors (NSCLC) Results details: Confirmed objective response rate (ORR) of 15.6% in all patients regardless of PD-L1 or HPV status Purple Biotech (NASDAQ: PPBT) Readout details: Ph1/2 study data of NT219 in combo w/ cetuximab Indication: SCCHN Results details: Effectively suppress cancer stem cells (CSC) and promote resistance and tumor recurrence. -- 👋 I'm Dominic Vacchiano, Co-founder of BiopharmIQ by Amp. We provide biopharma data to help with your sales/BD activities. 📰 Each week we share clinical/regulatory/funding news in an easy-to-digest format. #biotech #biopharma #aacr24